V
Verseau Therapeutics
Verseau is the Macrophage Company Transforming Immunotherapy
About Verseau Therapeutics
Verseau Therapeutics is a biotech startup that operates in the field of cancer immunotherapies. The company's primary focus is on developing a new class of treatments that stimulate the conversion of certain types of cells, specifically M2 macrophages, into a different type, M1 macrophages. This process, known as macrophage repolarization, triggers a coordinated immune response to combat cancer. In simpler terms, Verseau is working on a way to make the body's own immune system more effective in fighting cancer.
Read full description
The company's proprietary discovery engine, a unique tool that helps them identify and validate potential targets for treatment, has already identified over 20 targets for regulating cell biology. Their two main programs, which focus on PSGL-1 and VSIG4, are making significant progress towards clinical trials.
Verseau's clients are primarily in the healthcare sector, including hospitals, clinics, and other medical institutions, as well as individual patients suffering from cancer. The company operates in the biotech market, which is highly competitive and research-intensive.
Verseau's business model is based on research and development of innovative cancer treatments. The company invests heavily in research to discover and develop new therapies, which are then patented and sold to healthcare providers. The company makes money by selling these patented therapies and treatments.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Newton, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 59.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, radar de l'innovation, observatoire greentech, DT and LS, science-based
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Verseau Therapeutics.
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Verseau Therapeutics is 820 monthly website visits, up 256.5% over the last three months. Verseau Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
3SBio
20/20 HealthCare Partners
Highlight Capital
Alexandria Venture Investments
Yonghua Capital
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Verseau Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Verseau Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.